Want to see JP:4925 full AI Analyst Report?

HABA Laboratories, Inc. (4925) Price & Analysis

1 Followers

4925 Stock Chart & Stats

¥1748.00

¥4.00(0.23%)

At close: Jul 30 4:00 PM EDT

¥1748.00

¥4.00(0.23%)

Day’s Range― - ―

52-Week Range¥1,651.00 - ¥1,849.00

Previous CloseN/A

Volume300.00

Average Volume (3M)2.14K

Market Cap

¥6.52B

Enterprise Value¥2.27K

Total Cash (Recent Filing)¥5.78B

Total Debt (Recent Filing)¥1.19B

Price to Earnings (P/E)9.6

Beta0.27

Next Earnings

Nov 06, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield2.32%

Share Statistics

EPS (TTM)201.07

Shares Outstanding3,935,000

10 Day Avg. Volume2,940

30 Day Avg. Volume2,136

Financial Highlights & Ratios

PEG Ratio0.27

Price to Book (P/B)0.67

Price to Sales (P/S)0.53

P/FCF Ratio5.54

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Profitability TurnaroundThe return to profitability, supported by consistently high gross margins, indicates improved operating economics and product-level resilience. If maintained, this creates a stronger base for reinvestment and more dependable earnings over the next several quarters.

Conservative Balance SheetLow and improving leverage gives HABA financial flexibility to absorb operating volatility, fund its business, or support shareholders without heavy debt-service pressure. The sizable equity base also reduces balance-sheet risk during weaker demand periods.

Recent Cash GenerationFree cash flow tracking net income supports the quality of the recent earnings recovery and provides internally generated funds for operations and capital needs. This reduces reliance on external financing if the recent cash conversion persists.

Bears Say

Modest Net MarginThe gap between strong gross margins and a modest net margin suggests operating expenses and other costs absorb much of the value created at the product level. This leaves limited earnings cushion if costs rise or demand weakens.

Limited Revenue GrowthRevenue stabilization is constructive but does not yet demonstrate a durable growth trajectory. Without sustained top-line expansion, future earnings improvement may depend mainly on cost control and margin management rather than broadening demand.

Cash-Flow VolatilityRecent cash generation is encouraging, but the earlier volatility shows that earnings and cash conversion have not been consistently reliable across periods. This may constrain debt reduction and investment planning if weaker cash flow returns.

4925 FAQ

What was HABA Laboratories, Inc.’s price range in the past 12 months?

HABA Laboratories, Inc. lowest stock price was ¥1651.00 and its highest was ¥1849.00 in the past 12 months.

What is HABA Laboratories, Inc.’s market cap?

HABA Laboratories, Inc.’s market cap is ¥6.52B.

When is HABA Laboratories, Inc.’s upcoming earnings report date?

HABA Laboratories, Inc.’s upcoming earnings report date is Nov 06, 2026 which is in 70 days.

How were HABA Laboratories, Inc.’s earnings last quarter?

HABA Laboratories, Inc. released its earnings results on Aug 14, 2026. The company reported -¥10.23 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.

Is HABA Laboratories, Inc. overvalued?

According to Wall Street analysts HABA Laboratories, Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does HABA Laboratories, Inc. pay dividends?

HABA Laboratories, Inc. pays a Annually dividend of ¥40 which represents an annual dividend yield of 2.32%. See more information on HABA Laboratories, Inc. dividends here

What is HABA Laboratories, Inc.’s EPS estimate?

HABA Laboratories, Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does HABA Laboratories, Inc. have?

HABA Laboratories, Inc. has 3,935,000 shares outstanding.

What happened to HABA Laboratories, Inc.’s price movement after its last earnings report?

HABA Laboratories, Inc. reported an EPS of -¥10.23 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.114%.

Which hedge fund is a major shareholder of HABA Laboratories, Inc.?

Currently, no hedge funds are holding shares in JP:4925

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

HABA Laboratories, Inc.

Established in Tokyo, Japan, in 1983, HABA Laboratories, Inc. develops and distributes a comprehensive range of skincare, hair, and body care items both domestically and across international markets. Their skincare portfolio encompasses facial cleansers, toners, specialized treatments, and squalane oils, while their hair and body offerings include shampoos, conditioners, soaps, and various hair and hand care solutions. Consumers can acquire these products through multiple avenues, such as mail order, their online platform, various retail outlets including drug and variety stores, and at around 70 dedicated HABA shops located in major department stores and shopping complexes.